0001567619-22-014909.txt : 20220803
0001567619-22-014909.hdr.sgml : 20220803
20220803213949
ACCESSION NUMBER: 0001567619-22-014909
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220801
FILED AS OF DATE: 20220803
DATE AS OF CHANGE: 20220803
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Garren Hideki
CENTRAL INDEX KEY: 0001854126
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35676
FILM NUMBER: 221134343
MAIL ADDRESS:
STREET 1: C/O PROTHENA BIOSCIENCES INC
STREET 2: 331 OYSTER POINT BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PROTHENA CORP PUBLIC LTD CO
CENTRAL INDEX KEY: 0001559053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C
STREET 2: GRAND CANAL DOCKLANDS
CITY: DUBLIN 2
STATE: L2
ZIP: D02 VK60
BUSINESS PHONE: 011-353-1-236-2500
MAIL ADDRESS:
STREET 1: 77 SIR JOHN ROGERSON'S QUAY, BLOCK C
STREET 2: GRAND CANAL DOCKLANDS
CITY: DUBLIN 2
STATE: L2
ZIP: D02 VK60
FORMER COMPANY:
FORMER CONFORMED NAME: Prothena Corp plc
DATE OF NAME CHANGE: 20121102
FORMER COMPANY:
FORMER CONFORMED NAME: Neotope Corp Ltd
DATE OF NAME CHANGE: 20120926
4
1
doc1.xml
FORM 4
X0306
4
2022-08-01
0
0001559053
PROTHENA CORP PUBLIC LTD CO
PRTA
0001854126
Garren Hideki
C/O PROTHENA BIOSCIENCES INC
331 OYSTER POINT BOULEVARD
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Medical Officer
Ordinary Shares, par value $0.01 per share
2022-08-01
4
M
0
4000
24.90
A
4000
D
Ordinary Shares, par value $0.01 per share
2022-08-01
4
S
0
4000
30.52
D
0
D
Stock Option (Right to Buy)
24.9
2022-08-01
4
M
0
4000
0
D
2031-04-05
Ordinary Shares
4000
238000
D
The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 5, 2022 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
/s/ Michael Malecek, as attorney-in-fact for Hideki Garren
2022-08-03